J.P. Morgan Roundtable: Biotech Executives Expect Capital To Flow Despite Lower Valuations
This article was originally published in Scrip
Executive Summary
Informa Pharma's Global Director of Content Mike Ward and Scrip Intelligence West Coast Editor Mandy Jackson moderated a roundtable discussion on Jan. 11, the opening day of the 34th Annual J.P. Morgan Healthcare Conference, in San Francisco during which they spoke with eight biotechnology veterans about the state of biotech going into 2016.
You may also be interested in...
Case Studies: How Three Public Companies Financed R&D In A Tough Market
The market for public offerings by biopharma companies is tough, but Corbus Pharmaceuticals, Loxo Oncology and Novavax used three different strategies to raise cash from new and existing shareholders.
Italfarmaco To Seek Givinostat Approvals After Phase III Success In DMD
Italfarmaco’s HDAC inhibitor helped ambulatory Duchenne muscular dystrophy patients climb stairs faster than non-treated boys while Capricor’s cell therapy improved upper limb function in non-ambulatory patients.
Finance Watch: Venture Floodgates Open With New Funds, Dozens Of Rounds
Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.